# Ultra Clean Holdings, Inc.: financial statements, quarterly UCTT · Nasdaq · CIK 1275014 · [Technology](/sectors/technology.md) · fiscal year ends Dec 30 Pages: [Overview](/companies/uctt.md) · [Financials](/companies/uctt/financials.md) · [Filings](/companies/uctt/filings.md) · [Insiders](/companies/uctt/insiders.md) Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/uctt/financials.md?period=annual). ## Income statement | Line item | Unit | Q3 FY2023 (2023-09-29) | Q4 FY2023 (2023-12-29) | Q1 FY2024 (2024-03-29) | Q2 FY2024 (2024-06-28) | Q3 FY2024 (2024-09-27) | Q4 FY2024 (2024-12-27) | Q1 FY2025 (2025-03-28) | Q2 FY2025 (2025-06-27) | Q3 FY2025 (2025-09-26) | Q4 FY2025 (2025-12-26) | Q1 FY2026 (2026-03-27) | Q2 FY2026 (2026-06-26) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [435](/filings/0000950170-23-060220.md) | [445 d](/filings/0001628280-25-007865.md) | [478](/filings/0001628280-25-020658.md) | [516](/filings/0001628280-25-036413.md) | [540](/filings/0001628280-25-047117.md) | [563 d](/filings/0001628280-25-007865.md) | [519](/filings/0001628280-26-028365.md) | [519](/filings/0001628280-26-052540.md) | [510](/filings/0001628280-25-047117.md) | [507 d](/filings/0001628280-26-010744.md) | [534](/filings/0001628280-26-028365.md) | [645](/filings/0001628280-26-052540.md) | | Cost of revenue | $m | [370](/filings/0001628280-24-044152.md) | [374 d](/filings/0001628280-26-010744.md) | [395](/filings/0001628280-25-020658.md) | [428](/filings/0001628280-25-036413.md) | [447](/filings/0001628280-25-047117.md) | [472 d](/filings/0001628280-26-010744.md) | [435](/filings/0001628280-26-028365.md) | [439](/filings/0001628280-26-052540.md) | [428](/filings/0001628280-25-047117.md) | [429 d](/filings/0001628280-26-010744.md) | [449](/filings/0001628280-26-028365.md) | [541](/filings/0001628280-26-052540.md) | | Gross profit | $m | [65.2](/filings/0001628280-24-044152.md) | [71.0 d](/filings/0001628280-26-010744.md) | [82.6](/filings/0001628280-25-020658.md) | [88.5](/filings/0001628280-25-036413.md) | [93.4](/filings/0001628280-25-047117.md) | [91.8 d](/filings/0001628280-26-010744.md) | [84.0](/filings/0001628280-26-028365.md) | [79.5](/filings/0001628280-26-052540.md) | [82.2](/filings/0001628280-25-047117.md) | [77.3 d](/filings/0001628280-26-010744.md) | [84.4](/filings/0001628280-26-028365.md) | [104](/filings/0001628280-26-052540.md) | | Research and development | $m | [7.4](/filings/0001628280-24-044152.md) | [6.6 d](/filings/0001628280-26-010744.md) | [7.0](/filings/0001628280-25-020658.md) | [7.1](/filings/0001628280-25-036413.md) | [7.1](/filings/0001628280-25-047117.md) | [7.1 d](/filings/0001628280-26-010744.md) | [7.6](/filings/0001628280-26-028365.md) | [7.8](/filings/0001628280-26-052540.md) | [7.8](/filings/0001628280-25-047117.md) | [8.8 d](/filings/0001628280-26-010744.md) | [8.5](/filings/0001628280-26-028365.md) | [8.8](/filings/0001628280-26-052540.md) | | Operating income | $m | [5.7](/filings/0001628280-24-044152.md) | [4.5 d](/filings/0001628280-26-010744.md) | [17.3](/filings/0001628280-25-020658.md) | [22.9](/filings/0001628280-25-036413.md) | [25.2](/filings/0001628280-25-047117.md) | [25.9 d](/filings/0001628280-26-010744.md) | [12.9](/filings/0001628280-26-028365.md) | [(142)](/filings/0001628280-26-052540.md) | [10.6](/filings/0001628280-25-047117.md) | [10.9 d](/filings/0001628280-26-010744.md) | [11.4](/filings/0001628280-26-028365.md) | [29.5](/filings/0001628280-26-052540.md) | | Interest expense | $m | [12.3](/filings/0000950170-23-060220.md) | [12.9 d](/filings/0000950170-24-027213.md) | [12.2](/filings/0001628280-24-020679.md) | [11.7](/filings/0001628280-25-036413.md) | [12.0](/filings/0001628280-25-047117.md) | [10.7 d](/filings/0001628280-26-010744.md) | [9.9](/filings/0001628280-26-028365.md) | [10.1](/filings/0001628280-26-052540.md) | [9.9](/filings/0001628280-25-047117.md) | [8.4 d](/filings/0001628280-26-010744.md) | [7.3](/filings/0001628280-26-028365.md) | [1.1](/filings/0001628280-26-052540.md) | | Income tax | $m | [5.3](/filings/0001628280-24-044152.md) | [(6.2) d](/filings/0001628280-26-010744.md) | [9.9](/filings/0001628280-25-020658.md) | [8.5](/filings/0001628280-25-036413.md) | [9.9](/filings/0001628280-25-047117.md) | [4.5 d](/filings/0001628280-26-010744.md) | [7.4](/filings/0001628280-26-028365.md) | [7.2](/filings/0001628280-26-052540.md) | [8.7](/filings/0001628280-25-047117.md) | [2.6 d](/filings/0001628280-26-010744.md) | [19.2](/filings/0001628280-26-028365.md) | [18.1](/filings/0001628280-26-052540.md) | | Net income | $m | [(14.5)](/filings/0001628280-24-044152.md) | [(3.8) d](/filings/0001628280-26-010744.md) | [(9.4)](/filings/0001628280-25-020658.md) | [19.1](/filings/0001628280-25-036413.md) | [(2.3)](/filings/0001628280-25-047117.md) | [16.3 d](/filings/0001628280-26-010744.md) | [(5.0)](/filings/0001628280-26-028365.md) | [(162)](/filings/0001628280-26-052540.md) | [(10.9)](/filings/0001628280-25-047117.md) | [(3.3) d](/filings/0001628280-26-010744.md) | [(17.9)](/filings/0001628280-26-028365.md) | [8.7](/filings/0001628280-26-052540.md) | | Diluted EPS | $ per share | [(0.32)](/filings/0001628280-24-044152.md) | not reported | [(0.21)](/filings/0001628280-25-020658.md) | [0.42](/filings/0001628280-25-036413.md) | [(0.05)](/filings/0001628280-25-047117.md) | not reported | [(0.11)](/filings/0001628280-26-028365.md) | [(3.58)](/filings/0001628280-26-052540.md) | [(0.24)](/filings/0001628280-25-047117.md) | not reported | [(0.40)](/filings/0001628280-26-028365.md) | [0.19](/filings/0001628280-26-052540.md) | | Basic EPS | $ per share | [(0.32)](/filings/0001628280-24-044152.md) | not reported | [(0.21)](/filings/0001628280-25-020658.md) | [0.43](/filings/0001628280-25-036413.md) | [(0.05)](/filings/0001628280-25-047117.md) | not reported | [(0.11)](/filings/0001628280-26-028365.md) | [(3.58)](/filings/0001628280-26-052540.md) | [(0.24)](/filings/0001628280-25-047117.md) | not reported | [(0.40)](/filings/0001628280-26-028365.md) | [0.19](/filings/0001628280-26-052540.md) | - Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax - Cost of revenue: us-gaap:CostOfRevenue - Gross profit: us-gaap:GrossProfit - Research and development: us-gaap:ResearchAndDevelopmentExpense - Operating income: us-gaap:OperatingIncomeLoss - Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating - Income tax: us-gaap:IncomeTaxExpenseBenefit - Net income: us-gaap:NetIncomeLoss - Diluted EPS: us-gaap:EarningsPerShareDiluted - Basic EPS: us-gaap:EarningsPerShareBasic ## Balance sheet | Line item | Unit | Q3 FY2023 (2023-09-29) | FY2023 (2023-12-29) | Q1 FY2024 (2024-03-29) | Q2 FY2024 (2024-06-28) | Q3 FY2024 (2024-09-27) | FY2024 (2024-12-27) | Q1 FY2025 (2025-03-28) | Q2 FY2025 (2025-06-27) | Q3 FY2025 (2025-09-26) | FY2025 (2025-12-26) | Q1 FY2026 (2026-03-27) | Q2 FY2026 (2026-06-26) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Cash and equivalents | $m | [342](/filings/0000950170-23-060220.md) | [307](/filings/0001628280-25-007865.md) | [293](/filings/0001628280-24-020679.md) | [320](/filings/0001628280-24-033152.md) | [318](/filings/0001628280-24-044152.md) | [314](/filings/0001628280-26-010744.md) | [318](/filings/0001628280-25-020658.md) | [327](/filings/0001628280-25-036413.md) | [314](/filings/0001628280-25-047117.md) | [312](/filings/0001628280-26-052540.md) | [324](/filings/0001628280-26-028365.md) | [256](/filings/0001628280-26-052540.md) | | Current assets | $m | [926](/filings/0000950170-23-060220.md) | [893](/filings/0001628280-25-007865.md) | [909](/filings/0001628280-24-020679.md) | [961](/filings/0001628280-24-033152.md) | [986](/filings/0001628280-24-044152.md) | [970](/filings/0001628280-26-010744.md) | [948](/filings/0001628280-25-020658.md) | [956](/filings/0001628280-25-036413.md) | [941](/filings/0001628280-25-047117.md) | [960](/filings/0001628280-26-052540.md) | [1,098](/filings/0001628280-26-028365.md) | [1,161](/filings/0001628280-26-052540.md) | | Total assets | $m | [1,846](/filings/0000950170-23-060220.md) | [1,868](/filings/0001628280-25-007865.md) | [1,888](/filings/0001628280-24-020679.md) | [1,927](/filings/0001628280-24-033152.md) | [1,948](/filings/0001628280-24-044152.md) | [1,920](/filings/0001628280-26-010744.md) | [1,891](/filings/0001628280-25-020658.md) | [1,746](/filings/0001628280-25-036413.md) | [1,721](/filings/0001628280-25-047117.md) | [1,729](/filings/0001628280-26-052540.md) | [1,855](/filings/0001628280-26-028365.md) | [1,918](/filings/0001628280-26-052540.md) | | Current liabilities | $m | [294](/filings/0000950170-23-060220.md) | [310](/filings/0001628280-25-007865.md) | [329](/filings/0001628280-24-020679.md) | [351](/filings/0001628280-24-033152.md) | [359](/filings/0001628280-24-044152.md) | [336](/filings/0001628280-26-010744.md) | [313](/filings/0001628280-25-020658.md) | [312](/filings/0001628280-25-036413.md) | [293](/filings/0001628280-25-047117.md) | [301](/filings/0001628280-26-052540.md) | [358](/filings/0001628280-26-028365.md) | [425](/filings/0001628280-26-052540.md) | | Total liabilities | $m | [950](/filings/0000950170-23-060220.md) | [971](/filings/0001628280-25-007865.md) | [999](/filings/0001628280-24-020679.md) | [1,016](/filings/0001628280-24-033152.md) | [1,025](/filings/0001628280-24-044152.md) | [984](/filings/0001628280-26-010744.md) | [954](/filings/0001628280-25-020658.md) | [956](/filings/0001628280-25-036413.md) | [939](/filings/0001628280-25-047117.md) | [945](/filings/0001628280-26-052540.md) | [1,153](/filings/0001628280-26-028365.md) | [1,201](/filings/0001628280-26-052540.md) | | Long-term debt | $m | not reported | not reported | not reported | not reported | not reported | [500](/filings/0001628280-25-007865.md) | not reported | not reported | not reported | [467](/filings/0001628280-26-052540.md) | [602](/filings/0001628280-26-028365.md) | [599](/filings/0001628280-26-052540.md) | | Current portion of debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | [9.9](/filings/0001628280-26-052540.md) | [0.0](/filings/0001628280-26-028365.md) | [0.0](/filings/0001628280-26-052540.md) | | Shareholders' equity | $m | [838](/filings/0000950170-23-060220.md) | [839](/filings/0001628280-25-007865.md) | [831](/filings/0001628280-24-020679.md) | [852](/filings/0001628280-24-033152.md) | [858](/filings/0001628280-24-044152.md) | [874](/filings/0001628280-26-010744.md) | [872](/filings/0001628280-25-020658.md) | [719](/filings/0001628280-25-036413.md) | [710](/filings/0001628280-25-047117.md) | [711](/filings/0001628280-26-052540.md) | [628](/filings/0001628280-26-028365.md) | [640](/filings/0001628280-26-052540.md) | - Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue - Current assets: us-gaap:AssetsCurrent - Total assets: us-gaap:Assets - Current liabilities: us-gaap:LiabilitiesCurrent - Total liabilities: us-gaap:Liabilities - Long-term debt: us-gaap:LongTermDebt, us-gaap:LongTermDebtNoncurrent - Current portion of debt: us-gaap:LongTermDebtCurrent - Shareholders' equity: us-gaap:StockholdersEquity ## Cash flow | Line item | Unit | Q3 FY2023 (2023-09-29) | Q4 FY2023 (2023-12-29) | Q1 FY2024 (2024-03-29) | Q2 FY2024 (2024-06-28) | Q3 FY2024 (2024-09-27) | Q4 FY2024 (2024-12-27) | Q1 FY2025 (2025-03-28) | Q2 FY2025 (2025-06-27) | Q3 FY2025 (2025-09-26) | Q4 FY2025 (2025-12-26) | Q1 FY2026 (2026-03-27) | Q2 FY2026 (2026-06-26) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Operating cash flow | $m | [36.2 d](/filings/0001628280-24-044152.md) | [35.3 d](/filings/0001628280-26-010744.md) | [9.8](/filings/0001628280-25-020658.md) | [23.2 d](/filings/0001628280-25-036413.md) | [14.9 d](/filings/0001628280-25-047117.md) | [17.1 d](/filings/0001628280-26-010744.md) | [28.2](/filings/0001628280-26-028365.md) | [29.2 d](/filings/0001628280-26-052540.md) | [0.1 d](/filings/0001628280-25-047117.md) | [8.1 d](/filings/0001628280-26-010744.md) | [(33.3)](/filings/0001628280-26-028365.md) | [(41.1) d](/filings/0001628280-26-052540.md) | | Capital expenditure | $m | [12.2 d](/filings/0001628280-24-044152.md) | [16.6 d](/filings/0001628280-26-010744.md) | [18.0](/filings/0001628280-25-020658.md) | [13.0 d](/filings/0001628280-25-036413.md) | [15.2 d](/filings/0001628280-25-047117.md) | [17.3 d](/filings/0001628280-26-010744.md) | [12.4](/filings/0001628280-26-028365.md) | [16.8 d](/filings/0001628280-26-052540.md) | [11.0 d](/filings/0001628280-25-047117.md) | [10.1 d](/filings/0001628280-26-010744.md) | [9.6](/filings/0001628280-26-028365.md) | [16.2 d](/filings/0001628280-26-052540.md) | | Share repurchases | $m | [0.0 d](/filings/0001628280-24-044152.md) | [5.7 d](/filings/0001628280-26-010744.md) | [0.0](/filings/0001628280-24-020679.md) | [0.0 d](/filings/0001628280-25-036413.md) | [0.0 d](/filings/0001628280-25-047117.md) | [0.0 d](/filings/0001628280-26-010744.md) | [0.0](/filings/0001628280-26-028365.md) | [3.4 d](/filings/0001628280-26-052540.md) | [0.0 d](/filings/0001628280-25-047117.md) | [0.0 d](/filings/0001628280-26-010744.md) | [40.0](/filings/0001628280-26-028365.md) | [0.0 d](/filings/0001628280-26-052540.md) | - Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities - Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment - Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock ## Shares | Line item | Unit | Q3 FY2022 (2022-09-30) | Q3 FY2023 (2023-03-31) | Q3 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-29) | Q1 FY2024 (2024-03-29) | Q2 FY2024 (2024-06-28) | Q3 FY2024 (2024-09-27) | Q1 FY2025 (2025-03-28) | Q2 FY2025 (2025-06-27) | Q3 FY2025 (2025-09-26) | Q1 FY2026 (2026-03-27) | Q2 FY2026 (2026-06-26) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Diluted shares (weighted) | millions of shares | [0.0](/filings/0000950170-23-060220.md) | [44.8](/filings/0001628280-24-020679.md) | [44.7](/filings/0001628280-24-033152.md) | [44.8](/filings/0001628280-24-044152.md) | [44.6](/filings/0001628280-25-020658.md) | [45.4](/filings/0001628280-25-036413.md) | [45.0](/filings/0001628280-25-047117.md) | [45.1](/filings/0001628280-26-028365.md) | [45.2](/filings/0001628280-26-052540.md) | [45.4](/filings/0001628280-25-047117.md) | [45.3](/filings/0001628280-26-028365.md) | [46.1](/filings/0001628280-26-052540.md) | - Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding Shares outstanding: 45,277,029 at 2026-07-29, from the cover of the [10-Q filed 2026-08-04](/filings/0001628280-26-052540.md) (dei:EntityCommonStockSharesOutstanding). Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:35 ET. No prices; not investment advice.